News and Press Releases
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20 January 2026 -- Sandwich, UK -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 20, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
Evonik and Ethris enter strategic partnership to expand offerings for nucleic acid delivery
Developing and manufacturing innovative LNP delivery technology for respiratory medicine and beyond Expanding Evonik’s CDMO offerings, enabling efficient translation from concept to clinic Accelerating RNA-based therapeutic solutions for customers through...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2025
Terumo BCT and PwC Belgium Join Forces to Break Barriers in Access to Advanced Cell and Gene Therapies
2 September 2025 -- Brussels, Belgium -- Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, and PwC Belgium today announce a new collaboration focused on driving equitable...
Category: Biotechnology, Drug Discovery, Logistics, Manufacturing and Packing
Posted: September 8, 2025
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
University of Oxford and ReciBioPharm expand strategic collaboration in fight against malaria
Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials Delivers the sixth malaria vaccine candidate for the University of Oxford Provides drug...
Category: Biotechnology, Clinical Trials, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 9, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025
ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025
Therapeutic Oligonucleotides 2025: Drugging the Undruggable takes place at AstraZeneca in Gothenburg, Sweden from 14–15 May 25 March 2025 -- Cambridge, UK -- ELRIG, a not-for-profit, volunteer-led organisation for the drug...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritis Pivotal clinical trial in osteoarthritis patients on track to start in 2025. 4 March 2025 -- Liege, Belgium -- Allegro...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: March 4, 2025
ELRIG Announces Drs Jue Wang and Robert Grundy as Keynote Speakers at Research & Innovation 2025
24 January 2025 -- Cambridge, UK -- The European Laboratory Research & Innovation Group (ELRIG), a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Research...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 24, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
Paris voted the ‘heart of pharma’ in Europe
Pharmapack Europe research reveals Île-de-France is the second-best location in Europe for ‘drug manufacturing’ and to ‘start a biotech’ Paris, France – The global drug delivery and packaging industry arrives...
Category:
Posted: January 13, 2025
Paris Expo, Porte de Versailles - Hall 7.2 | Paris, France
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation...
Category: BioManufacturing, Drug Discovery
Posted: December 11, 2024
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA
